Skip to the page
pepts.wiki

We are not doctors and nothing here is medical advice. Always consult a medical professional first. Why we say this

Phase 3 trialsStub

Mazdutide

Dual GLP-1 and glucagon receptor agonist

A once-weekly peptide that acts on the GLP-1 and glucagon receptors, studied in phase 3 trials in obesity and type 2 diabetes.

Reconstitution calculator

At a glance

Phase 3 trials

Large randomized trials in people are running or published. It is not a licensed medicine.

This page is a stub

The wiki has this compound's identity from the My-Pepts library, its standing, and what PubMed holds for it. The article, with its studies read and cited, is not written yet. Until it is, the counts below say how much research exists, not what it found.

How strong is the evidence

How far it has climbed

Every medicine climbs the same ladder. Most compounds never reach the top, and where one stands says how much its claims can carry.

  1. Licensed medicine

    A regulator has reviewed the trials and licensed it for a named use.

  2. Phase 3: Mazdutide

    Large randomized trials, often thousands of people, against placebo or a standard treatment.

  3. Phase 2

    Mid-sized trials that measure dose against effect in people with the condition.

  4. Phase 1 and early human studies

    First studies in people: safety, and how the body handles it.

  5. Cells and animals

    Laboratory and animal work. An animal result is not a result in people.

58
papers on PubMed
38
of them in people
9
randomized trials
30
reviews

A count says how much has been published, not what it found. Counted on PubMed: 2026-11-16

Handling and reconstitution

From powder to a measured sample

The same four steps for any lyophilized vial. Laboratory handling, not use in a person.

  1. 1. Read the vial

    The label gives the mass of peptide in the vial, in milligrams. That number is the start of every calculation.

  2. 2. Add the diluent

    A measured volume of diluent goes in slowly, down the glass. Swirl gently; shaking can damage a peptide.

  3. 3. Work out the strength

    Concentration is mass divided by volume: 10 mg in 2 mL is 5 mg per mL.

  4. 4. Measure the sample

    Volume is the mass wanted divided by the concentration. On a U-100 syringe, 1 mL is 100 units.

The calculator below does the arithmetic and shows its working.

As powder

General practice for lyophilized peptides: keep the sealed vial frozen or refrigerated, dry and away from light, and follow the supplier's certificate of analysis.

In solution

Once in solution a peptide is kept refrigerated and used within the period the supplier states. A vial drawn from more than once needs a preserved diluent such as bacteriostatic water.

This is general practice for lyophilized peptides, not data on Mazdutide itself. The batch's certificate of analysis and the supplier's sheet are the facts to go by. More on storage

Reconstitution calculator

Opens on vial sizes common for research peptides. Change any number. How the arithmetic works

Draw to

10 units

0.1 mL on a U-100 syringe

Concentration
2.5 mg/mL
Each unit holds
25 mcg
Samples in the vial
20
Sample
250 mcg

5 mg in 2 mL is 2.5 mg/mL. 250 mcg of that is 0.1 mL, which reads as 10 units. This is arithmetic for a vial of Mazdutide; no amount here is a recommendation.

Mazdutide: on PubMed

What PubMed held for Mazdutide on November 16, 2026. A count says how much a compound has been studied, not what the studies found: how to read these numbers.

58
papers
38
in humans
9
clinical trials
9
randomized trials
2012: 0 papers122013: 0 papers2014: 0 papers142015: 0 papers2016: 0 papers162017: 0 papers2018: 0 papers182019: 0 papers2020: 0 papers202021: 0 papers2022: 1 papers222023: 1 papers2024: 8 papers242025: 20 papers2026: 34 papers so far26
Papers per year, 2012 to 2026. The most in one year: 34.

Most relevant on PubMed

Listed by PubMed's own relevance ranking, trials and reviews first. The wiki has not read these into the article unless they are also among its sources.

  1. Comparative effects of drugs for adults with overweight or obesity: systematic review and network meta-analysis

    ReviewNong K, Shi Q, Xie X, et al. BMJ (Clinical research ed.), 2026. PMID 42419792

  2. Once-Weekly Mazdutide in Chinese Adults with Obesity or Overweight

    Randomized trialJi L, Jiang H, Bi Y, et al. The New England journal of medicine, 2025. PMID 40421736

  3. Emerging pharmacotherapies for obesity: A systematic review

    ReviewKokkorakis M, Chakhtoura M, Rhayem C, et al. Pharmacological reviews, 2025. PMID 39952695

  4. Efficacy and safety of Mazdutide on weight loss among diabetic and non-diabetic patients: a systematic review and meta-analysis of randomized controlled trials

    Meta-analysisNalisa DL, Cuboia N, Dyab E, et al. Frontiers in endocrinology, 2024. PMID 38440786

  5. Mazdutide Versus Dulaglutide for Weight Loss and Diabetes Management: Meta-Analysis of Randomized Clinical Trials

    Meta-analysisAyesh H, Ayesh S, Niswender K American journal of therapeutics, 2024. PMID 39292847

  6. A phase 2 randomised controlled trial of mazdutide in Chinese overweight adults or adults with obesity

    Randomized trialJi L, Jiang H, Cheng Z, et al. Nature communications, 2023. PMID 38092790

  7. Mazdutide: First Approval

    ReviewShirley M Drugs, 2025. PMID 41028652

  8. Mazdutide versus placebo in Chinese adults with type 2 diabetes

    Randomized trialZhu D, Zhao J, Cai H, et al. Nature, 2026. PMID 41407859

Search used: ("Mazdutide"[tiab]). Run it on PubMed

Research links

Also in Metabolic